Please ensure Javascript is enabled for purposes of website accessibility
Accessibility Menu
Paratek Pharmaceuticals Stock Quote

Paratek Pharmaceuticals (NASDAQ: PRTK)

Paratek Pharmaceuticals Return vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
PRTK -7.08% -76.89% -25.40% -86%
S&P +21.68% +73.88% +11.70% +150%

Paratek Pharmaceuticals Company Info

Paratek Pharmaceuticals, Inc. engages in the development and commercialization of therapies based upon tetracycline chemistry. Its products include omadacycline and sarecycline, which are used for the treatment of community-acquired bacterial infections, including community-acquired bacterial pneumonia, acute bacterial skin and skin structure infections and urinary tract infections. The company was founded by Walter Gilbert and Stuart B. Levy in 1996 and is headquartered in Boston, MA.

News & Analysis

Valuation

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.